The company plans to include 180 patients in the study at around 20 clinics in Sweden. The results from the trial are expected in the second half of 2008.
Peter Wolpert, CEO of Moberg Derma, said: “We recently received the approval from the Swedish Medical Products Agency and Ethical Committee and will now initiate our second Phase III study. If the promising data from our previous Phase II trial can be reproduced in this larger study, we will be able to offer patients a novel and efficacious topical treatment for seborrheic dermatitis of the scalp.”